Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

NCT02784171 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02784171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02784171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2/3
Overall status
Completed
Start date
November 11, 2016
Completion date
October 11, 2024
Enrollment
520 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma